Skip to main content

Table 2 Individual characteristics, treatments and outcomes in 17 cases of Burkholderia primary colonisation

From: Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis Centres: a pilot study

Patient No.CentreBurkholderia SpeciesCo-pathogensAge (years)FEV1% at PCTreatment (molecules, routes of administration and duration)Consistency antibiogram/
antibiotic therapya
Outcome
1MB. multivoransMRSA, PA1971PO Levofloxacin and Cotrimoxazole 21 days; INH Aztreonam 28 daysYes (3/3)Eradication
2MB. multivoransMRSA, PA, Fungie2379PO Cotrimoxazole; INH Aztreonam, 28 daysYes (2/2)Eradication
3MB. multivoransMSSA, Fungie2894IV Ceftazidime and Tobramycin, 14 daysNo (1/2)Persistence
4bBB. multivoransMRSA1331IV Ceftazidime and Gentamicin, 14 daysNo (1/2)Persistence
5TB. multivorans 6113Not treated Eradicationc
6TB. multivoransMSSA, PA, Fungie21105Not treated Persistence
7T, BB. cenocepacia IIIAMRSA, Sten1087IV Ceftazidime and Ciprofloxacin, 14 daysYes (2/2)Eradicationc
8MB. cenocepacia IIIBSten, MB1852PO Ciprofloxacin; INH Aztreonam, 28 daysNo (0/2)Eradicationc
9TB. cenocepacia IIIAMRSA
PA
1959IV Piperacillin-tazobactam and Ciprofloxacin, 14 daysNo (1/2)dPersistence
10MB. cenocepacia IIIAPA2262IV Temocillin and Tobramycin, 14 days; PO Cotrimoxazole, 28 daysYes (2/3)Persistence
11MB. contaminansPA, MB3326Not treated Eradicationc
12T, MB. vietnamiensisMSSA17109Not treated Eradication
13BB. ambifariaMSSA783IV Ceftazidime and Tobramycin, 14 daysNo (1/2)Persistence
14TUnidentified BCCMSSA16106IV Ceftazidime and Ciprofloxacin; INH Tobramycin, 14 daysYes (3/3)Eradicationc
15BB. gladioliMSSA14112IV Piperacillin-tazobactam; INH Tobramycin, 14 daysYes (2/2)Eradication
16TB. gladioliSten3499Not treated Eradication
17TB. gladioliMSSA, Fungie3265Not treated Persistence
  1. FEV1 Forced Expiratory Volume in one second, B Bordeaux, M Montpellier, T Toulouse, BCC Burkholderia cepacia complex, MB Mycobacteria, MSSA, Methicillin-Susceptible Staphylococcus aureus, MRSA Methicillin-Resistant Staphylococcus aureus, PA Pseudomonas aeruginosa, Sten Stenotrophomonas maltophilia, PO per os, IV intravenous, INH inhaled
  2. a Consistency antibiogram/antibiotic therapy: in vitro full susceptibility to at least two of the antibiotics used, or to at least one antibiotic if combined with inhaled tobramycin. All BCC were resistant to IV aminoglycosides (natural resistance)
  3. b This patient underwent lung transplantation and colonisation disappeared following surgery
  4. c Single isolate
  5. d The strain was only susceptible to ciprofloxacin
  6. e Concerning fungi repartition: patient No 2 Aspergillus fumigatus; Patient No 3 Aspergillus spp.; Patient No 6 Candida albicans; Patient No 17 Aspergillus fumigatus and Candida albicans